— Know what they know.
Not Investment Advice

APUS

Apimeds Pharmaceuticals US, Inc
1W: +2.3% 1M: +33.6% 3M: +4.2% YTD: +4.8%
$1.75
+0.04 (+2.34%)
 
AMEX · Healthcare · Drug Manufacturers - Specialty & Generic · $22.0M · Alpha Radar Buy · Power 63
Smart Money Score
No convergence signal
Key Statistics
Market Cap$22.0M
52W Range0.951-4.031
Volume61,175
Avg Volume170,185
Beta3.71
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOVinod Menon
Employees2
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2025-05-09
2 East Broad Street
Hopewell, NJ 08525
US
808-209-7887
About Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.

Recent Insider Trades

NameTypeSharesPriceDate
Weintraub Bennett A-Award 10,000 $2.67 2025-11-11
Yoon Hankil A-Award 10,000 $2.67 2025-11-11
Koo Jakap A-Award 10,000 $2.67 2025-11-11
O'DONNELL CAROL A A-Award 10,000 $2.67 2025-11-11
Kogan Elona A-Award 10,000 $2.67 2025-11-11

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms